Background: Umbilical cord mesenchymal stem cells (UCMSCs) derived exosomes could simulate the function of MSC and avoid the limitations of MSC, which is being hotspot in the research of rheumatoid arthritis (RA) treatment. Chemokines recruit inflammatory cells and osteoclasts in inflammatory joints, and participate in the synovial inflammation and bone destruction of RA. The mechanisms of UCMSC- derived exosomes on chemokines have less understood in RA.

Objectives: The aim of this study was to investigate the effect of UCMSC and UCMC-derived exosomes on the chemokines CCL2, CXCL10 and CXCL12 in CIA rats.

Methods: Human umbilical cord mesenchymal stem cells (UCMSCs) were cultured in vitro and separated using a differential centrifugation methods. UCMSCs exosomes low and high concentration groups. Rats in UCMSCs group were injected in double ankle joint with UCMSCs 2X10^6/L weekly for 3 weeks. Rats in UCMSCs exosomes low and high group were injected in double ankle joint with UCMSCs exosomes 30ug and 90ug weekly for 3 weeks, respectively. Rats in MTX group were given intraperitoneal injection with MTX (0.9mg/kg) weekly for 3 weeks. For the CIA rats, the joint swelling index was recorded and the protein expressions of CCL2, CXCL10 in synovial tissue were detected by immunohistochemistry. CCL2, CXCL10 and CXCL12 mRNA levels in synovial joint and spleen were measured by reverse transcription-polymerase chain reaction (RT-PCR).

Results: Intrarticular injection of UCMSC exosomes decreased CCL2 and CXCL12 levels in serum and improved synovial hyperplasia and inflammatory cell infiltration in the CIA rats. UCMSC exosomes suppressed the protein expressions of CCL2, CXCL10, CXCL12 in synovial tissue. It also inhibited transcript levels of CCL2, CXCL10, CXCL12 in synovial tissue and spleen. UCMSC had similar effect on CCL2, CXCL10, CXCL12 in CIA rats. The high concentration group was more effective than the low concentration in preventing CCL2, CXCL10, CXCL12 protein expressions of synovial tissue and CCL2 transcript level of spleen.

Conclusion: UCMSC exosomes alleviate synovial inflammation in CIA rats through suppression of CCL2, CXCL10, CXCL12 release. The inhibitory effect of on chemokines simulate UCMSC, their cell of origin, the high concentration was better than low concentration.

REFERENCES

Disclosure of Interests: None declared

Rheumatoid arthritis - comorbidity and clinical aspects

Toshiaki Aizawa1, Tetsuya Kawano1, Takeshi Kashiwagura4, Naohisa Miyakoshi2, Yochi Shmotade3. 1Kitaakita Municipal Hospital, Akita, Japan; 2Akita City Hospital, Akita, Japan; 3Akita University Graduate School of Medicine, Akita, Japan

Background: While nonsteroidal anti-inflammatory drugs (NSAIDs) are the most frequently used therapeutic agents, they are known to cause side effects, such as gastrointestinal disorders and kidney dysfunction. As the proportion of patients with chronic kidney disease (CKD) increases with age, dealing with NSAIDs requires particular care in areas with aging populations. However, in many cases, prescriptions are continued without any particular plan. Hence, the effects of acetaminophen (AAP), which does not cause kidney dysfunction, are being revisited. Opportunities are increasing for using formulations containing tramadol hydrochloride in patients with chronic pain or intravenous agents for perioperative pain management.

Objectives: In this study, we investigated the kidney functions of patients with musculoskeletal disease who had been using NSAIDs for a long time and examined the possibility of switching to AAP.

Methods: The subjects were 105 patients with musculoskeletal disease (42 men and 63 women) who were being treated as outpatients in the orthopedics department of our hospital and had been using NSAIDs for at least 3 months. They primarily had 5 musculoskeletal diseases, including degenerative osteoarthritis (OA), rheumatoid arthritis (RA), osteoporosis (OP), polymyalgia rheumatica (PMR), and gout (G). After checking their background characteristics, we measured their kidney functions and visual analogue scale (VAS) scores, and then switched them from NSAIDs to AAP. Kidney functions were evaluated by classifying CKD using glomerular filtration rate (eGFR) and urinary protein, and by using the Cockcroft-Gault equation to calculate creatinine clearance (Ccr). The patients were given the NSAIDs that they had been taking for single use. Six months after the switch, we remeasured kidney functions and VAS scores, and investigated whether they could continue using AAP and whether they had used NSAIDs.

Results: The patients’ mean age at the time of switching from NSAIDs to AAP was 76 years, and their mean duration of NSAID use was 43 months. For the diseases, 63 patients had OA, 20 had RA, 14 had OP, 8 had PMR and 2 had G. Before the switch, the mean VAS score was 41.6 mm and mean eGFR was 67.0 mL/min/1.73 m². On the basis of the eGFR, the CKD classification was G3 or higher in 38.1% of patients. The CKD classifications with the amounts of urinary protein added to the eGFR were as follows: green, 44.7%; yellow, 33.0%; orange, 14.6%; and red, 7.8%, with 55.4% classified as having CKD. By age, the proportions of patients with chronic kidney disease (CKD) increased with age, dealing with NSAIDs requires particular care in areas with aging populations. However, in many cases, prescriptions are continued without any particular plan. Hence, the effects of acetaminophen (AAP), which does not cause kidney dysfunction, are being revisited. Opportunities are increasing for using formulations containing tramadol hydrochloride in patients with chronic pain or intravenous agents for perioperative pain management.

REFERENCES
Disclosure of Interests: None declared

**AB0293**

**ASSOCIATION OF HOMOCYSTEINE WITH BONE MINERAL DENSITY IN RHEUMATOID ARTHRITIS PATIENTS**

Antonio Alvarez de Cienfuegos 1, Lucia Cantero-Nieto 2, José Alberto García-Gómez 2, Jose Luis Callejas-Rubio 3, Miguel A. González-Gay 3, Norberto Ortego 4.

1 Vega Baja Hospital, Rheumatology, Orihuela, Spain; 2Santa Ana Hospital, Granada, Spain; 3Hospital General Universitari d’Eix, Elche, Spain; 4Hospital Universitario San Cecilio, Unit of Systemic Autoimmune Diseases-Internal Medicine, Granada, Spain; 5IDIVAL, Santander, Spain

**Background:** Rheumatoid arthritis (RA) is a chronic inflammatory autoimmune disease with unknown etiology that primarily affects the peripheral joints and, over time, leads to loss of mobility if untreated. RA is an important risk factor for osteoporosis and occurrence of fractures. Many authors describe a significantly higher frequency of osteoporosis and fractures in patients with RA in comparison to a control group. The aetiology of progressive bone mass loss in RA patients is multifactorial and remains obscure. Factors related to the pathological process – activity of RA and applied therapy – seem to be significant. Homocysteine (Hcy) is a sulfhydryl containing amino acid produced by demethylation of an essential amino acid (methionine). A high serum level of Hcy has been recently recognized as a risk factor for osteoporosis and osteoporotic fractures in postmenopausal women.

**Objectives:** The purpose of this study was to evaluate serum Hcy levels in RA patients compared with healthy controls, examine possible associations between Hcy and bone mineral density (BMD) and study smoking habits.

**Methods:** This cross-sectional study was performed in Vega-Baja Hospital, Orihuela (Spain) from November 2016 to May 2018. We prospectively enrolled 63 consecutive women patients affected by RA and followed at the Vega-Baja Hospital (Orihuela, Spain) and 60 matched healthy women controls. All patients included in this study had normal serum creatinine (Cr) levels and met the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA. Serum Hcy was analyzed using immunonephelometric method. Bone mineral density (BMD) of femoral neck and lumbar spine was measured by dual-energy X-ray absorptiometry (DXA).

**Results:** A total of 63 female patients were included in our study, with a mean (SD) age of 53 ± 8 years. The majority were Caucasian (90.5%). Thirty-four patients were menopausal and twenty-nine non-menopausal patients. The mean duration of RA was 8.5 ± 5.8 years. The mean disease activity scores in 28 joints (DAS28) according to the erythrocyte sedimentation rate (ESR) indicated low disease activity 3.0 ± 1.3. The mean health assessment questionnaire (HAQ) was 0.75 ± 0.67. Twenty-eight patients were treated with methotrexate, with a median weekly dose of 11.5 ± 4.8 mg, all the patients received 10 mg folic acid supplementation per week. Serum Hcy concentrations were significantly higher in the RA patients than those in the control group: [9.93 (5.6-18.8) vs. 7.11 (4.9-11.1), pg/mL; P<0.001]. Serum levels of Hcy were inversely related to lumbar spine BMD and femur neck BMD (r = -0.28; P < 0.05).

**Conclusion:** Patients with RA have high levels of Hcy that correlate inversely, with bone mass suggesting that hyperhomocysteinemia is a risk factor for osteoporosis in patients with RA.

**REFERENCES**


**Disclosure of Interests:** Antonio Alvarez de Cienfuegos: None declared, Lucia Cantero-Nieto: None declared, José Alberto García-Gómez: None declared, Jose Luis Callejas-Rubio: None declared, Miguel A González-Gay: Grant/research support from: Prof. MA González-Gay received grants/ research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker’s bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Norberto Ortego: None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7766

**Disclosure of Interests:** Antonio Alvarez de Cienfuegos: None declared, Lucia Cantero-Nieto: None declared, José Alberto García-Gómez: None declared, Gema Robledo: None declared, Javier Martin Ibanez: None declared, Raquel Ríos Fernández: None declared, Miguel A. González-Gay: None declared, Norberto Ortego: None declared, Vega Baja Hospital, Rheumatology, Orihuela, Spain; Santa Ana Hospital, Granada, Spain; Hospital General Universitari d’Eix, Elche, Spain; Institute of Parasitology and Biomedicine López-Neyra, IPBLN-CSIC, Granada, Spain; Hospital Universitario San Cecilio, Unit of Systemic Autoimmune Diseases-Internal Medicine, Granada, Spain; IDIVAL, Santander, Spain

**Background:** Rheumatoid Arthritis (RA) is one of the chronic autoimmune diseases with an estimated prevalence of 1 to 2 percent of the total population in the world. RA patients have an increased risk of morbidity and mortality from cardiovascular (CV) events as a result of accelerated atherosclerosis. Endothelin-1 (ET-1) is a hormone with strong vasoconstrictor properties, secreted in excessive amounts by damaged endothelial cells. However, the effect of this hormone depends on the presence of specific ET-1 receptors as well as their density and location. ET-1 is a mediator-activating autocrine and paracrine, primarily in the circulatory system. It induces the production of proinflammatory cytokines, exacerbating the inflammatory process.

**Objectives:** The objectives of this study were: to compare serum ET-1 levels between RA patients and healthy controls and observe the relationship between tobacco smoking and serum levels of ET-1 in RA patients.

**Methods:** This cross-sectional study was performed in Vega-Baja Hospital, Orihuela (Spain) from November 2016 to May 2018. We prospectively enrolled 63 consecutive women patients affected by RA and followed at the Vega-Baja Hospital (Orihuela, Spain) and 65 matched healthy women controls. All patients included in this study had normal serum creatinine (Cr) levels and met the 2010 American College of Rheumatology/European League Against Rheumatism (ACR/EULAR) criteria for RA. Serum ET-1 was analyzed using ELISA.

**Results:** A total of 63 female patients were included in our study, with a mean (SD) age of 53 ± 8 years. The majority were Caucasian (90.5%). The mean duration of RA was 8.5 ± 5.8 years. The mean disease activity scores in 28 joints (DAS28) according to the erythrocyte sedimentation rate (ESR) indicated low disease activity 3.0 ± 1.3. The mean health assessment questionnaire (HAQ) was 0.75 ± 0.67. Fourteen (22%) patients had a smoking history. Serum ET-1 concentrations were significantly higher in the RA patients than those in the control group: [30.6 (0-50) vs. 21.7 (0-50), pg/mL; P<0.001]. Higher plasma ET-1 concentrations were significantly associated with smoking (r 0.29; p<0.05).

**Conclusion:** Our data shows a significant difference in the concentration of serum ET-1 between RA patients and controls. We report significant positive association between serum levels of ET-1 and smoking status.

**REFERENCES**


**Disclosure of Interests:** Antonio Alvarez de Cienfuegos: None declared, Lucia Cantero-Nieto: None declared, José Alberto García-Gómez: None declared, Gema Robledo: None declared, Javier Martin Ibanez: None declared, Raquel Ríos Fernández: None declared, Miguel A González-Gay: Grant/research support from: Prof. MA González-Gay received grants/ research supports from Abbvie, MSD, Jansen and Roche., Speakers bureau: Consultation fees/participation in company sponsored speaker’s bureau from Pfizer, Lilly, Sobi, Celgene, Novartis, Roche and Sanofi., Norberto Ortego: None declared

**DOI:** 10.1136/annrheumdis-2019-eular.7757